Monday, October 31, 2011 2:51:02 PM
No.
The company concerned would need to do a series of bridging studies that demonstrated to the Regulatory Agency's satisfaction that the two different formulations are bioequivalent, and if a straightforward bioequivalence study can't be done
- and for "wave-based information composites", I can envisage some minor technical challenges (LOL)-
then a full therapeutic equivalence study would have to be conducted, or possibly two.
And I have a feeling that might be problematic, because in the real universe that you and I inhabit, neither product has any efficacy whatsoever.
"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."
Upton Sinclair
"Nobody ever went broke underestimating the intelligence of the American public."
H. L. Mencken
Vocodia Enters Medical Alert Industry with Innovative Emergency Response Pendant • VHAI • Oct 25, 2024 8:00 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 • HYDI • Oct 24, 2024 11:18 AM
VAYK Asserts Goal of Q4 Operationally Profitable and Projects Major 2025 Launch • VAYK • Oct 24, 2024 10:40 AM
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push • CBDL • Oct 24, 2024 7:07 AM
ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • AVXL • Oct 23, 2024 8:03 AM
Forte Minerals to Acquire the Miscanthus Epithermal Gold and Porphyry Copper Prospects in Central Perú with Environmental Drilling Permit (DIA) • CUAU • Oct 23, 2024 7:38 AM